Design Therapeutics, Inc.
DSGN
$5.41
$0.214.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 15.26% | 14.88% | -14.89% | -23.59% | -22.33% |
| Gross Profit | -15.26% | -14.88% | 14.89% | 23.59% | 22.33% |
| SG&A Expenses | 5.21% | -6.72% | -14.64% | -20.54% | -12.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.21% | -3.58% | -20.22% | -26.26% | -23.48% |
| Operating Income | -18.21% | 3.58% | 20.22% | 26.26% | 23.48% |
| Income Before Tax | -25.65% | 4.22% | 25.84% | 33.97% | 31.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.65% | 4.22% | 25.84% | 33.97% | 31.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.65% | 4.22% | 25.84% | 33.97% | 31.97% |
| EBIT | -18.21% | 3.58% | 20.22% | 26.26% | 23.48% |
| EBITDA | -18.30% | 3.69% | 20.43% | 26.50% | 23.71% |
| EPS Basic | -24.56% | 5.19% | 26.65% | 34.57% | 32.43% |
| Normalized Basic EPS | -24.54% | 5.21% | 26.66% | 35.81% | 33.66% |
| EPS Diluted | -24.56% | 5.19% | 26.65% | 34.57% | 32.43% |
| Normalized Diluted EPS | -24.54% | 5.21% | 26.66% | 35.81% | 33.66% |
| Average Basic Shares Outstanding | 0.80% | 0.94% | 1.08% | 0.91% | 0.72% |
| Average Diluted Shares Outstanding | 0.80% | 0.94% | 1.08% | 0.91% | 0.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |